Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders: Workshop Summary by Sheena M. Posey Norris

Author:Sheena M. Posey Norris
Language: eng
Format: epub
Publisher: The National Academies Press
Published: 2015-10-27T00:00:00+00:00

___________________

1A severe form of epilepsy.

2Persisting and potentially life-threatening seizure activity despite anticonvulsant treatment.

3Mary O’Donovan, executive director of regulatory affairs at BioMarin Pharmaceutical Inc.

4

Patient Benefit and Engagement

Highlights

Patients and caregivers can provide crucial information about what kind of risks they would be willing to accept in exchange for a possible new therapeutic agent in any given clinical situation (Boutin, Chiarello, and Maderis).

Value determinations for potential treatments might include consideration about impact on caregivers as well as patients; preventive medicines—including those that delay onset of serious nervous system disorders—can deliver tremendous benefits to patients and caregivers alike (Comas-Herrera).

Public−private partnerships and advocacy groups could contribute significantly to activities that might bolster pharmaceutical company pursuit of CNS drugs (Boutin, Hyman, Kennedy, and Reddy).

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.